Personalized medicine with biologics for severe type 2 asthma: current status and future prospects

Biologic Therapies of Immunologic Diseases

(2017) Bradley E. Chipps et al.   IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA

A randomized multicenter study evaluating Xolair persistence of response after long-term therapy

(2017) Dennis Ledford et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Current and future biomarkers in allergic asthma

(2016) U. M. Zissler et al.   ALLERGY

Biomarkers in the clinical development of asthma therapies

(2016) Tracy L Staton et al.   Biomarkers in Medicine

Biomarkers and asthma management

(2016) Hannah K. Bayes et al.   Current Opinion in Allergy and Clinical Immunology

Targeted Therapy for Older Patients with Uncontrolled Severe Asthma: Current and Future Prospects

(2016) E. W. de Roos et al.   DRUGS & AGING

Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis

(2016) Claus Bachert et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

(2016) Eugene R Bleecker et al.   LANCET

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

(2016) Sally Wenzel et al.   LANCET

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) J Mark FitzGerald et al.   LANCET

A tissue checkpoint regulates type 2 immunity

(2016) Steven J Van Dyken et al.   NATURE IMMUNOLOGY

Alternative splicing of interleukin-33 and type 2 inflammation in asthma

(2016) Erin D. Gordon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Detailed analysis of sputum and systemic inflammation in asthma phenotypes: are paucigranulocytic asthmatics really non-inflammatory?

(2016) Sophie Demarche et al.   BMC Pulmonary Medicine

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

(2016) Nicola A Hanania et al.   Lancet Respiratory Medicine

Emerging molecular phenotypes of asthma

(2015) Anuradha Ray et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Evolving Concepts of Asthma

(2015) Marc Gauthier et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Stratified medicine in inflammatory disorders: From theory to practice

(2015) Joseph R. Arron et al.   CLINICAL IMMUNOLOGY

A summary of the new GINA strategy: a roadmap to asthma control

(2015) Helen K. Reddel et al.   EUROPEAN RESPIRATORY JOURNAL

Asthma phenotypes and the use of biologic medications in asthma and allergic disease: The next steps toward personalized care

(2015) Merritt L. Fajt et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Innate immunological function of TH2 cells in vivo

(2015) Liying Guo et al.   NATURE IMMUNOLOGY

The immunology of asthma

(2015) Bart N Lambrecht et al.   NATURE IMMUNOLOGY

T H 2 and T H 17 inflammatory pathways are reciprocally regulated in asthma

(2015) David F. Choy et al.   Science Translational Medicine

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

(2015) Nicola A Hanania et al.   THORAX

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

(2015) Mario Castro et al.   Lancet Respiratory Medicine

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial

(2015) Christopher E Brightling et al.   Lancet Respiratory Medicine

Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data

(2014) Wei Wu et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

TH17 Cells Mediate Steroid-Resistant Airway Inflammation and Airway Hyperresponsiveness in Mice

(2014) L. McKinley et al.   JOURNAL OF IMMUNOLOGY

The complex relationship between inflammation and lung function in severe asthma

(2014) M L Manni et al.   Mucosal Immunology

Clinical development success rates for investigational drugs

(2014) Michael Hay et al.   NATURE BIOTECHNOLOGY

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exploring the Effects of Omalizumab in Allergic Asthma

(2013) Nicola A. Hanania et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy

(2013) Nicola A. Hanania et al.   ANNALS OF INTERNAL MEDICINE

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

(2013) K. F. Chung et al.   EUROPEAN RESPIRATORY JOURNAL

Structural Basis of Signaling Blockade by Anti-IL-13 Antibody Lebrikizumab

(2013) Mark Ultsch et al.   JOURNAL OF MOLECULAR BIOLOGY

A Large Subgroup of Mild-to-Moderate Asthma Is Persistently Noneosinophilic

(2012) Kelly Wong McGrath et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

(2012) Edward Piper et al.   EUROPEAN RESPIRATORY JOURNAL

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

(2012) Ian D Pavord et al.   LANCET

Asthma phenotypes: the evolution from clinical to molecular approaches

(2012) Sally E Wenzel   NATURE MEDICINE

Reslizumab for Poorly Controlled, Eosinophilic Asthma

(2011) Mario Castro et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Cytokine/anti-cytokine therapy - novel treatments for asthma?

(2011) Philip M Hansbro et al.   BRITISH JOURNAL OF PHARMACOLOGY

Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation

(2011) Anne E. Dixon et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The burden of adult asthma in the United States: Evidence from the Medical Expenditure Panel Survey

(2011) Patrick W. Sullivan et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Lebrikizumab Treatment in Adults with Asthma

(2011) Jonathan Corren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of Exhaled Nitric Oxide Measurement to Identify a Reactive, at-Risk Phenotype among Patients with Asthma

(2010) Raed A. Dweik et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

(2010) Roland Kolbeck et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma

(2009) Prescott G. Woodruff et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program

(2009) Wendy C. Moore et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma

(2009) Bob Lanier et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma

(2009) Pranabashis Haldar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia

(2009) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

The development of allergic inflammation

(2008) Stephen J. Galli et al.   NATURE